Author: sugaradmin

Introduction and Objective: Metabolic dysfunction-associated steatohepatitis (MASH) is a leading cause of cirrhosis. NIS2+™is a novel blood-based diagnostic test developed to identify “at-risk” MASH (steatohepatitis with significant fibrosis stage ≥F2) that combines miR-34a-5p (microRNA linked to altered lipid metabolism) and YKL-40 (biomarker of fibrosis). Our aim was to assess the prevalence of “at-risk” MASH by […]

Introduction and Objective: There is a gap in understanding diabetes technology use among older people with type 1 and type 2 diabetes (pwt1d, pwt2d). A survey in Germany, Austria and Switzerland investigated the association between age and diabetes technology use.Methods: Between 2023/11 and 2024/01, pwd and parents of children with diabetes reported their use of […]

Introduction and Objective: Non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are closely associated with an increased risk of congestive heart failure (CHF). This study aimed to evaluate the long-term incidence of CHF in patients with NAFLD according to glycemic status, using a nationwide cohort of Korean adults.Methods: This longitudinal cohort study […]

Introduction and Objective: AZD6234, a long-acting amylin analog in clinical development for weight management, reduces body weight (BW) in diet-induced obese (DIO) rats without a loss of lean mass. Semaglutide, a GLP-1R agonist, reduces BW with both fat mass and lean mass loss. Here, we aim to understand the impact of combined treatment of AZD6234 […]

Introduction and Objective: While β cell dysfunction represents a key pathogenetic factor in T2D onset, collecting appropriate pancreatic samples from metabolically profiled donors has proven challenging. In this study, we investigate possible mirroring between in vivo insulin secretion and ex vivo islet function of subjects with and without T2D.Methods: 36 subjects in list for pancreatectomy […]

Introduction and Objective: A recent trial of tirzepatide (SURMOUNT) found a 92% reduction of diabetes incidence among patients with overweight or obesity over three years. Our objective was to estimate the potential population, outcomes, and cost associated with use of tirzepatide for the primary prevention of DM.Methods: Data from the 2021-2023 cycle of the National […]

Introduction and Objective: The STRIDE trial (NCT04560998) demonstrated that once weekly semaglutide 1.0 mg significantly improved maximum walking distance (MWD) in people with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD) vs. placebo. Whether the benefits are consistent across T2D characteristics has not been described.Methods: The primary outcome in STRIDE, MWD measured on […]

Introduction and Objective: In SOUL (NCT03914326), oral semaglutide (sema) 14 mg QD, a GLP-1 receptor agonist, reduced major adverse cardiovascular (CV) event (MACE) risk by 14%. GLP-1RAs are routinely prescribed to reduce A1c and BMI in type 2 diabetes (T2D). Whether the CV benefits of oral sema are influenced by baseline A1c or BMI is […]

Introduction and Objective: This study evaluated the impact of an interactive virtual assistant device, programmed with a behavioral intervention model, on mental-health and diabetes-related outcomes in older adults with type 2 diabetes (T2D)Methods: We conducted a randomized controlled trial enrolling participants aged 65 years or older with T2D. Participants were randomized to receive a Smart […]